Jui-Yi Chen
Overview
Explore the profile of Jui-Yi Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang C, Chang L, Sheu J, Huang Y, Chen J, Lai C, et al.
Hypertens Res
. 2025 Mar;
PMID: 40069399
Emerging evidence has suggested a significant prevalence of mild autonomous cortisol secretion (MACS) among patients diagnosed with primary aldosteronism (PA). However, MACS's clinical characteristics and implications in PA patients remain...
2.
Lai H, Chen J, Wu V, See C
Cardiovasc Diabetol
. 2025 Mar;
24(1):110.
PMID: 40057763
The 2022 KDIGO guideline for diabetes management in patients with chronic kidney disease (CKD) had endorsed the use of GLP-1 receptor agonists (GLP-1RAs) for patients with CKD and type 2...
3.
Lin L, Chen J, Huang T, Wu V
Cardiovasc Diabetol
. 2025 Feb;
24(1):87.
PMID: 39984953
Background: Cardiovascular disease is a leading cause of post-transplant mortality in kidney transplant recipients (KTRs), especially those with diabetes. Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular and...
4.
Liao H, Cheng C, Chen H, Chen J, Pan H, Huang T, et al.
Clin Kidney J
. 2025 Feb;
18(2):sfae385.
PMID: 39927258
Background: Dipeptidyl peptidase 4 inhibitors (DPP4is) are considered safe for use in patients with diabetes mellitus and kidney dysfunction. We explored whether usage of DPP4is in patients who recovered from...
5.
Yang T, Chuang M, Lin H, Wu V, Pan H, Chou Y, et al.
BMJ Open
. 2025 Feb;
15(2):e092752.
PMID: 39920047
Objectives: Immune checkpoint inhibitors (ICPi) have significantly improved survival for patients with advanced cancers. However, the occurrence of ICPi-associated acute kidney injury (AKI) and its clinical impact remains unclear. This...
6.
Huang C, Huang T, Yang Y, Chang MBBS L, Tu Y, Wu V, et al.
J Am Heart Assoc
. 2025 Feb;
14(3):e038714.
PMID: 39895534
Background: The object of this study was to investigate the incidence rate of major adverse cardiovascular event (MACE) among patients with primary aldosteronism (PA) after adrenalectomy or mineralocorticoid receptor antagonist...
7.
Chen J, Hsu T, Liu J, Pan H, Lai C, Yang S, et al.
Am J Kidney Dis
. 2025 Jan;
PMID: 39863261
Rationale & Objective: Glucagon-like peptide 1 (GLP-1) receptor agonists improve cardiac and kidney outcomes in patients with diabetes; however, their efficacy in individuals with reduced estimated glomerular filtration rate (eGFR)...
8.
Kao T, Chen J, Liu J, Tseng W, Hsieh C, Wu V, et al.
Ther Adv Endocrinol Metab
. 2024 Dec;
15:20420188241303429.
PMID: 39669529
Background: The aldosterone-to-renin ratio (ARR) is commonly used for screening primary aldosteronism (PA) in patients with difficult-to-control hypertension. Various thresholds have been proposed for the confirmatory tests, leading to inconsistency...
9.
Sheu J, Chang L, Chen J, Pan H, Tseng C, Chueh J, et al.
Nat Commun
. 2024 Nov;
15(1):10043.
PMID: 39567483
Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) have demonstrated efficacy in reducing cardiovascular events and potentially improving kidney function in diabetic patients. This investigation analyzes the TriNetX database to assess the efficacy...
10.
Chang L, Liao H, Chen J, Wu V
J Clin Endocrinol Metab
. 2024 Nov;
PMID: 39535770
Context: Patients with diabetes are prone to acute kidney injury with the potential transition to chronic kidney disease. Few studies have investigated the role of thiazolidinedione (TZD) in these patients...